Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients

医学 内科学 乳腺癌 曲妥珠单抗 肿瘤科 卡铂 多西紫杉醇 胃肠病学 化疗 癌症 顺铂
作者
Yibo Chen,Tianyi Zhang,Rui Zhang,X B Cao
出处
期刊:Cancer Biotherapy and Radiopharmaceuticals [Mary Ann Liebert, Inc.]
卷期号:39 (6): 435-440
标识
DOI:10.1089/cbr.2023.0175
摘要

Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed. Clinical response by Response Evaluation Criteria in Solid Tumors (RECIST), pathological complete response (pCR), and adverse events data was retrieved. Results: According to the RECIST, the complete response rate was 0.0%, 10.5%, and 15.8% after second-cycle, fourth-cycle, and sixth-cycle therapy, respectively; whereas the objective response rate was 76.3%, 92.1%, and 100.0%, accordingly. The total pCR (tpCR) rate was 52.6%, the pCR rate of the breast was also 52.6%, and the pCR rate of lymph nodes was 86.8%. The tpCR rate was lower in patients with HER2 immunohistochemistry (IHC)++ and amplification by fluorescent in situ hybridization (FISH) than in those with HER2 IHC+++ (14.3% vs. 61.3%, p = 0.024), which was also lower in patients with Ki-67 expression ≥30% than in those with Ki-67 expression <30% (40.0% vs. 76.9%, p = 0.031). The common adverse events included diarrhea (84.2%), anemia (73.7%), nausea and vomiting (63.2%), fatigue (50.0%), hypomagnesemia (44.7%), leukopenia (42.1%), thrombocytopenia (39.5%), elevated transaminase (36.8%), and pruritus (31.6%). Conclusions: Pyrotinib and trastuzumab plus chemotherapy serve as an acceptable neoadjuvant regimen exhibiting good efficacy and tolerance in HER2+ breast cancer patients, while further large-scale validation is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武鸽子发布了新的文献求助10
刚刚
小蘑菇应助忆枫采纳,获得10
刚刚
刘柳完成签到 ,获得积分10
1秒前
1秒前
2秒前
王雪发布了新的文献求助20
2秒前
恒牙完成签到 ,获得积分10
3秒前
聪慧雅霜完成签到,获得积分10
3秒前
3秒前
研友_Lw4Ngn完成签到,获得积分10
3秒前
慕青应助iFaceDOG采纳,获得10
3秒前
从容安柏发布了新的文献求助10
4秒前
天天快乐应助jinxixi采纳,获得10
4秒前
niupotr完成签到,获得积分10
4秒前
5秒前
Ava应助Tong123采纳,获得10
5秒前
烟花应助淡淡宛采纳,获得10
6秒前
Weilang完成签到,获得积分10
6秒前
zz完成签到,获得积分10
7秒前
dll完成签到 ,获得积分10
7秒前
十六完成签到,获得积分10
7秒前
8秒前
快乐冰淇淋完成签到,获得积分20
8秒前
丸子_2025000完成签到,获得积分10
8秒前
Lucas应助OKOK采纳,获得10
9秒前
猫科动物完成签到,获得积分10
9秒前
samchen完成签到,获得积分10
9秒前
星辰大海应助开心小猪采纳,获得10
10秒前
10秒前
科研杂役发布了新的文献求助10
10秒前
CX发布了新的文献求助10
10秒前
12秒前
12秒前
温柔体贴阿尔法完成签到,获得积分10
12秒前
13秒前
xue发布了新的文献求助10
13秒前
ll应助苏苏采纳,获得10
13秒前
秦从露完成签到 ,获得积分10
13秒前
asdfghjkl发布了新的文献求助10
14秒前
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970394
求助须知:如何正确求助?哪些是违规求助? 3515139
关于积分的说明 11177107
捐赠科研通 3250335
什么是DOI,文献DOI怎么找? 1795254
邀请新用户注册赠送积分活动 875732
科研通“疑难数据库(出版商)”最低求助积分说明 805054